Clinical Trials Logo

Cancer Pain clinical trials

View clinical trials related to Cancer Pain.

Filter by:

NCT ID: NCT04436705 Completed - Cancer-Related Pain Clinical Trials

The Effectiveness of Progressive Muscle Relaxation Technique in Reducing Cancer-related Pain

Start date: May 2016
Phase: N/A
Study type: Interventional

This randomized controlled trial was designed to evaluate the effectiveness of the Progressive Muscle Relaxation (PMR) technique in reducing Cancer-related Pain (CRP) in patients receiving palliative care in Jordan. The main hypothesis (H0) of this trial is that cancer patients receiving palliative care do not report a decrease in pain intensity levels and an improve in pain interferences with life activities as a result of participating in PMR technique to a significant extent compared to patients who do not participate. The sub-hypothesis (H1) of this trial is that cancer patients receiving palliative care report a decrease in pain intensity levels and an improve in pain interferences with life activities as a result of participating in PMR technique to a significant extent compared to patients who do not participate.

NCT ID: NCT04404933 Completed - Cancer Clinical Trials

Study of Opioid-Induced Constipation 2 Project

StOIC-2
Start date: August 21, 2017
Phase:
Study type: Observational

The aim of the project is to investigate OIC in a real world / diverse group of patients with cancer. The objectives of the project are to determine: a) efficacy of a treatment algorithm to manage OIC; b) efficacy of conventional laxatives to manage OIC; c) efficacy of PAMORAs / other interventions to manage OIC.

NCT ID: NCT04350112 Completed - Cancer Clinical Trials

Study of Opioid-Induced Constipation 1 Project

StOIC-1
Start date: August 21, 2017
Phase:
Study type: Observational

The aim of the project is to investigate opioid-induced constipation (OIC) in a real world / diverse group of patients with cancer. The objectives of the project are to determine: a) prevalence of OIC; b) clinical features / impact of OIC; c) management of OIC.

NCT ID: NCT04315831 Completed - Cancer Clinical Trials

Safety and Effectiveness of Transdermal Buprenorphine in Cancer Pain

SOOTHE
Start date: January 31, 2018
Phase:
Study type: Observational

Buprenorphine transdermal patch is newly available in Taiwan in June 2017, the trade name is Transtec, and the available dosages are 35 μg/h and 52.5 μg/h. Taiwan is the first Asia country which launched Transtec for cancer pain treatment. Although the efficacy of transdermal buprenorphine has been demonstrated in some randomized, placebo-controlled studies and also conducted a large scale post-marketing surveillance study in Germany, therefore the local scientific data is required for Asia experience. Due to above rationale, this observational study will be initiated in Taiwan, to build up the first real-world scientific data in Asia. The objective of this study is to collect the safety and effectiveness of transdermal buprenorphine in routine clinical practice, in particular, to collect data in population with controlled cancer pain and stable titration from previous opioid analgesics in Taiwan.

NCT ID: NCT04243954 Completed - Cancer Pain Clinical Trials

Intravenous vs Oral Analgesia in Cancer Patients With Severe Pain After Successful Titration

Start date: April 10, 2020
Phase: Phase 2
Study type: Interventional

Pain is one of the most common and fear symptoms for cancer patients, which seriously affects the quality of life in cancer patients. At present, oral opioid is the most common route to administrate cancer pain. However, the patients do not satisfy the pain administration with oral opioid after successful titration in many cases, especially the cases with severe cancer pain. Patient controlled analgesia (PCA) with hydromorphone can take analgesic effect rapidly. The aim of this trial is to compare the maintenance with hydromorphone PCA intravenously or switch to Sustained-Release Morphine orally after successful titraton with hydromorphone PCA intravenously in severe cancer pain.

NCT ID: NCT04219072 Completed - Breast Cancer Clinical Trials

Clinical Classification of Pain in Breast Cancer Survivors

Start date: July 1, 2023
Phase:
Study type: Observational

Breast cancer is the most common malignancy in women worldwide according to International Agency for Research on Cancer. Unfortunately, cancer survivors often face long-term symptoms that occur or persist after completion of treatment. In addition to fatigue, pain is the most common persistent symptom after cancer and cancer treatment. The diagnosis and treatment of pain in cancer survivors is not clear for many physicians. A mechanism-based classification of pain in cancer survivors might be a critical step for clinical reasoning, especially for discrimination of different pain types. The primary aim of this study is to determine the prevalence of the predominant type of pain in Turkish breast cancer survivors using a recent published clinical algorithm.

NCT ID: NCT04176575 Completed - Metastatic Cancer Clinical Trials

Balancing Method for Pain Related to Advanced Cancer

Start date: July 5, 2022
Phase: N/A
Study type: Interventional

Balancing Method for Pain Related to Advanced Cancer seeks to confirm the benefit of acupuncture for patients with pain related to advanced cancer.

NCT ID: NCT04162379 Completed - Clinical trials for Steroid Anlgesia in Cancer Pain

Oral Prednisolone Effect on Cancer WHO Stepladder Analgesia Protocol

Start date: November 15, 2019
Phase: Phase 2
Study type: Interventional

Introduction; World Health Organization (WHO) analgesic ladder; Step I recommends non-opioid analgesics for mild pain. Step II specifies the use of weak opioids for moderate pain. Step III comprises the use of strong opioids for severe pain. Cancer pain management using opioids administered alone or in combination with adjuvant analgesics. Corticosteroids adjuvant use for neuropathic and bone pain treatment. However, despite widespread use of corticosteroids, scientific evidence about its efficacy in cancer pain management is limited. This protocol aims to clarify pors and cons of interrupted steroid dosing in chronic cancer pain WHO stepladder analgesia protocol. Methods; Prospective quizi-pre-post experimental study will be conducted after IRB approval in the Mansoura oncology canter pain clinic-Faculty of medicine Mansoura University Egypt. Verbal informed consent will be obtained from the respondents (patients) for the interview. Furthermore, the data collected from each patient will be kept confidential and used strictly only for the purpose of the study. Patients will be allocated as single group and will take oral prednisolone (sulopride10 mg) single dose every two days for 4 successive weeks then the next two weeks as washout period (stop dosing gradually by taking 5 mgs for 3 successive dosing every 2nd day over a week, then stop the oral steroid drug totally over the 2nd week of the washout period. The second period of the study will start by taking the oral prednisolone (sulopride10 mg) every fourth day for the next 4 weeks after which the patient will get another washout two weeks period (stop dosing gradually 5 mgs for 3 successive dosing every 4th day then stop the drug totally).A questionnaire-based interview using Brief Pain Inventory-Short Form (BPI-sf) (16) based on VAS pain score as a rough tool for pain intensity Data collection: Primary Outcome: global Pain intensity, assessed by a visual analogue scale (VAS) 0-10. Secondary outcomes based on the Brief Pain Inventory short form (BPI-sf).

NCT ID: NCT03981809 Completed - Cancer Pain Clinical Trials

Screening Tool to Identify the Dominant Pain Mechanism in Cancer Survivors: PainsCan

PainsCan
Start date: June 13, 2019
Phase:
Study type: Observational [Patient Registry]

Development and internal validation of an easy-to-use tool for clinical pain assessment. The tool has to be applicable in any clinical practice and without the need for expensive and complicated hospital tools to identify the source of persistent pain after the treatment of cancer.

NCT ID: NCT03895762 Completed - Clinical trials for Breakthrough Cancer Pain

Observational Study of Efficacy, Safety and Tolerability of Fentanyl in Korean Cancer Patients

OASIS
Start date: July 4, 2017
Phase:
Study type: Observational

The purpose of this observational study is: To observe the efficacy, safety, and tolerability of Abstral ODT for the alleviation of breakthrough cancer pain in Korean patients with various cancers in real-world clinical settings and supplement and expand the previous cross-sectional survey results.